` ANAB (AnaptysBio Inc) vs S&P 500 Comparison - Alpha Spread

ANAB
vs
S&P 500

Over the past 12 months, ANAB has significantly outperformed S&P 500, delivering a return of +74% compared to the S&P 500's +13% growth.

Stocks Performance
ANAB vs S&P 500

Loading
ANAB
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ANAB vs S&P 500

Loading
ANAB
S&P 500
Difference
www.alphaspread.com

Performance By Year
ANAB vs S&P 500

Loading
ANAB
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
AnaptysBio Inc vs Peers

S&P 500
ANAB
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

AnaptysBio Inc
Glance View

Market Cap
958.8m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
44.65 USD
Undervaluation 22%
Intrinsic Value
Price
Back to Top